Tilray Brands (TLRY) Non-Current Deferred Tax Liability (2018 - 2026)
Tilray Brands' (TLRY) quarterly Non-Current Deferred Tax Liability came in at $40.3 million in Q2 2026, down 12.57% YoY from $46.1 million in Q2 2025, and up 411.54% on a QoQ basis from $7.9 million in Q1 2026.
Tilray Brands (TLRY) Non-Current Deferred Tax Liability (2018 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 9 years of Non-Current Deferred Tax Liability data on file, last reported at $40.3 million in Q2 2026.
- Quarterly Non-Current Deferred Tax Liability fell 12.57% year-over-year to $40.3 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $40.3 million (down 12.57% YoY) and the FY2026 annual result came in at $40.3 million, down 12.57% from the prior year.
- Non-Current Deferred Tax Liability advanced to $40.3 million in Q2 2026, from $7.9 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $244.5 million in Q2 2024 to a low of $1.9 million in Q3 2025.
- A 5-year average of $131.7 million and a median of $164.4 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability soared 46.09% — and 2025, when it sank 98.57%.
- Tracing TLRY's Non-Current Deferred Tax Liability over 5 years: stood at $180.1 million in 2022, then decreased by 7.58% to $166.5 million in 2023, then slipped by 24.32% to $126.0 million in 2024, then sank by 95.54% to $5.6 million in 2025, then surged by 616.72% to $40.3 million in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $40.3 million (Q2 2026), $7.9 million (Q1 2026), and $5.6 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Tilray Brands | 513.87 Mn | 279.24 Mn | 90.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 40.29 Mn |
| May 31, 2026 | 40.29 Mn |
| Feb 28, 2026 | 7.88 Mn |
| Feb 28, 2026 | 7.88 Mn |
| Nov 30, 2025 | 5.62 Mn |
| Nov 30, 2025 | 5.62 Mn |
| Aug 31, 2025 | 1.94 Mn |
| Aug 31, 2025 | 1.94 Mn |
| May 31, 2025 | 46.09 Mn |
| May 31, 2025 | 46.09 Mn |
| Nov 30, 2024 | 125.98 Mn |
| Nov 30, 2024 | 125.98 Mn |
| Aug 31, 2024 | 136.23 Mn |
| Aug 31, 2024 | 136.23 Mn |
| May 31, 2024 | 244.50 Mn |
| May 31, 2024 | 244.50 Mn |
| Feb 29, 2024 | 161.04 Mn |
| Feb 29, 2024 | 161.04 Mn |
| Nov 30, 2023 | 166.45 Mn |
| Nov 30, 2023 | 166.45 Mn |